James Hardie Industries plc JHX
Paragraphs with nothing like them in last year's 10-K
Fewer than two 10-Ks to compare.
Paragraphs in the 10-Q filed Nov 5, 2026 that were not in the one before
New in the latest 10-Q
36 paragraphs in the 10-Q filed Nov 5, 2026 with nothing like them in the 10-Q filed Aug 6, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
Financial statements and notes
As discussed in Note 3, “Discontinued Operations”, the Company entered into a definitive purchase agreement to sell its sustainable walling and flooring solutions business, Fermacell. The Company also intends to close the European fiber cement business. Fermacell and the European fiber cement business previously made up the Company’s Europe reportable segment. The previously reported amounts for the Europe segment have been reclassified to discontinued operations for all periods presented.
Read in the 10-Q
assets, or Other liabilities depending on their respective category, and Accrued interest has been reclassified from Accounts payable and accrued liabilities to Other liabilities.
Read in the 10-Q
On August 20, 2026, the Company entered into a definitive purchase agreement to sell its sustainable walling and flooring solutions business, Fermacell, located in Europe for € 840.0 million in cash, or approximately $ 980.0 million as of the date of the announcement, subject to customary adjustments for net debt and working capital as of closing. The Company also intends to close the European fiber cement business. Fermacell and the European fiber cement business previously made up the Company’s Europe reportable segment. The strategic divestiture of the European operations and the intended closure of the European fiber cement business will enable the Company to focus on the highest growth and return opportunities. The transaction is expected to close in the first half of calendar 2027, subject to customary closing conditions, including required regulatory approvals. Based on the current structure of the transaction, any gain recognized on the divestiture is expected to be exempt from Irish taxation under the Irish participation exemption regime, subject to satisfaction of the applicable statutory requirements at closing.
Read in the 10-Q
The pending divestiture of the European operations and the closure of the European fiber cement business meet the criteria to be accounted for as discontinued operations. Accordingly, the Company has applied discontinued operations treatment as required by Accounting Standards Codification (“ASC”) 205-20. The related assets and liabilities associated with the discontinued operations are classified as held for sale in the Condensed Consolidated Balance Sheets and the related operating results have been reclassified and presented as discontinued operations in the Condensed Consolidated Statements of
Read in the 10-Q
Operations for all periods presented. The Company’s Condensed Consolidated Statements of Cash Flows include the financial results of the Europe segment for all periods presented. Additionally, in accordance with ASC 360, the Company ceased recording depreciation and amortization for Europe’s property, plant and equipment, finite-lived intangible assets and lease right-of-use assets.
Read in the 10-Q
Show the other 31
During the three and six months ended September 30, 2026, the Company recorded $ 13.1 million of charges associated with the closure of the European fiber cement business, consisting of $ 6.8 million of impairment charges related to property, plant and equipment, $ 4.3 million of employee severance costs and $ 2.0 million of other shutdown-related costs. The other shutdown-related costs primarily consisted of inventory disposal costs, facility closure costs, and other applicable closure costs. The Company expects total closure-related costs to be approximately $ 26.0 million. Year to date costs incurred are included in income from discontinued operations, net of tax on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).
Read in the 10-Q
The following table represents the major classes of assets and liabilities of discontinued operations classified as held for sale in the Condensed Consolidated Balance Sheets as of September 30, 2026 and March 31, 2026:
Read in the 10-Q
1. Assets held for sale on the Condensed Consolidated Balance Sheets includes $ 10.6 million and $ 10.9 million at September 30, 2026 and March 31, 2026, respectively, related to ceasing manufacturing in the Philippines. The Philippines closure did not qualify for discontinued operations.
Read in the 10-Q
The following table presents the major components of discontinued operations, net of income taxes, in the Company's Condensed Consolidated Statements of Operations:
Read in the 10-Q
Cash flows related to discontinued operations have not been segregated and are included in the Condensed Consolidated Statements of Cash Flows for all periods presented. The following table provides select financial information related to cash flows from discontinued operations:
Read in the 10-Q
Six Months Ended September 30, (Millions of U.S. dollars) 2026 2025 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Cash flows from operating activities Depreciation and amortization $ 17.0 $ 14.1 Share-based compensation 1.3 0.7 Other, net 7.3 0.5 Accounts and other receivables 13.5 5.6 Accounts payable and accrued liabilities (13.2) 16.7 Income tax payable 5.8 0.7 Cash flows from investing activities Purchases of property, plant and equipment (16.3) (20.8)
Read in the 10-Q
The Company uses derivatives for risk management purposes and does not engage in speculative activity. A risk management objective for the Company is to mitigate interest rate risk associated with the Company’s external credit facilities and foreign currency risk primarily with respect to forecasted transactions denominated in foreign currencies. The determination of whether the Company enters into a derivative transaction to achieve these risk management objectives depends on a number of factors, including an evaluation of the extent to which derivative instruments will achieve such risk management objectives of the Company.
Read in the 10-Q
In August 2026, the Company entered into deal-contingent foreign currency forward contracts to manage the risk of depreciation of the Euro-denominated sales price related to the Fermacell divestiture. Deal-contingent foreign currency forward contracts had an aggregate notional amount of € 750.0 million. These derivative instruments were entered into as economic hedges and do not qualify for hedge accounting. The forward contracts are valued using models that maximize the use of market observable inputs including forward and spot prices for currencies and are categorized as Level 2 within the fair value hierarchy. The change in fair value of the deal-contingent forward contracts was a non-cash gain of $ 19.4 million for the three and six months ended September 30, 2026 and was recognized in Other (income) expense, net on the Company’s Condensed Consolidated Statements of Operations and Comprehensive Income (loss). See Note 3, “Discontinued Operations”, for further discussion regarding the Fermacell divestiture.
Read in the 10-Q
The following table sets forth the total outstanding notional amount and the fair value of the Company’s foreign currency forward contracts:
Read in the 10-Q
Fair Value as of (Millions of Euros and U.S. dollars) Notional Amount September 30, 2026 March 31, 2026 Derivatives not accounted for as hedges September 30, 2026 March 31, 2026 Assets Liabilities Assets Liabilities Foreign currency forward contracts € 750.0 € $ 19.4 $ $ $
Read in the 10-Q
The following table summarizes the Company’s share-based compensation grants for the six months ended September 30, 2026:
Read in the 10-Q
Grant Price per Share Restricted stock units 1,529,398 A$ 36.28 Performance-based restricted stock units 599,129 A$ 38.07 Market condition restricted stock units 256,770 A$ 28.71 Stock options 163,281 A$ 18.37
Read in the 10-Q
The following includes the assumptions used to fair value the RSU grants (market condition) and stock options for the six months ended September 30, 2026:
Read in the 10-Q
On August 20, 2026, the board of directors approved and authorized a new share repurchase program for an aggregate amount up to $ 250.0 million through August 20, 2027. For the three months ended September 30, 2026, no repurchases were made under this program and $ 250.0 million remained available for repurchase as of September 30, 2026.
Read in the 10-Q
Due to the announcement of the strategic divestiture, the results of the Europe segment are excluded from the Company’s segment results and are presented within discontinued operations. Prior-period segment information has been recast to exclude the discontinued operations. Refer to Note 3, “Discontinued Operations” for more information on the Company’s discontinued operations.
Read in the 10-Q
Net sales increased 24% due to higher net sales in all of our reportable segments, as further described below.
Read in the 10-Q
Gross margin increased 6.6 percentage points primarily driven by a $47.9 million inventory step-up adjustment related to recording the acquired inventory of AZEK at fair value in the second quarter of fiscal year 2026 which did not repeat in the current corresponding period. This was partially offset by higher intangible asset amortization following the finalization of the purchase price allocation related to the AZEK acquisition. Intangible asset amortization expense was $16.0 million in the second quarter of fiscal year 2027 compared to $12.4 million in the prior corresponding period.
Read in the 10-Q
associated with the divestiture of our European operations and closure of our European fiber cement business.
Read in the 10-Q
Interest, net decreased 18% primarily due to lower interest expense following the repayment of our $400.0 million senior unsecured notes in June 2026 and the repayment of our €400.0 million senior unsecured notes in December 2025.
Read in the 10-Q
Other income, net increased due to a $19.4 million non-cash gain on the foreign currency forward contracts entered into to hedge our exposure to fluctuations in exchange rates associated with the anticipated Euro-denominated proceeds from the sale of our Fermacell business.
Read in the 10-Q
the AZEK acquisition was $32.0 million for the six months ended September 30, 2026, compared to $12.4 million in the prior corresponding period.
Read in the 10-Q
Acquisition and divestiture related expenses decreased 80% primarily due to lower professional service fees and labor costs, including severance, retention and stock-based compensation costs associated with the AZEK acquisition. These costs include divestiture related expenses of $9.3 million for the six months ended September 30, 2026, related to our European operations divestiture and closure of our European fiber cement business. Acquisition related expenses of $22.2 million and $158.3 million for the six months ended September 30, 2026 and 2025, respectively, include costs associated with the AZEK acquisition and ongoing integration.
Read in the 10-Q
Acquisition and divestiture related expenses increased 24% driven by a $1.7 million inventory write-off associated with the divestiture of our European operations, partially offset by a $0.8 million decrease in acquisition related costs associated with the AZEK acquisition and ongoing integration.
Read in the 10-Q
Net sales increased 51% primarily driven by higher volumes from expanded distribution, including our initial load-in at Boise Cascade, and our annual price increase.
Read in the 10-Q
Gross margin increased 13.9 percentage points primarily driven by a $36.7 million inventory step-up adjustment related to recording the acquired inventory of AZEK at fair value in fiscal year 2026 which did not recur in the current period.
Read in the 10-Q
SG&A expenses increased 175%, driven by an additional three months of expenses in the current year. As a percentage of sales, SG&A expenses increased 0.4 percentage points primarily due to higher intangible asset amortization following the finalization of the purchase price allocation related to the AZEK acquisition as discussed above. Intangible asset amortization expense was $91.8 million for the six months ended September 30, 2026, compared to $27.1 million in the prior corresponding period. This
Read in the 10-Q
R&D expenses increased 112% primarily due to an additional three months of expenses associated with AZEK business in the current year.
Read in the 10-Q
General corporate costs decreased 47%, driven by a $138.6 million decrease in acquisition related expenses, driven by the factors discussed in the quarter-over-quarter discussion above, partially offset by higher stock-based compensation costs and divestiture related costs incurred in the current year of $7.6 million. Higher stock compensation expense was mainly due to timing of grants and an increase in stock price for the six months ended September 30, 2026 compared to a decrease in stock price in the prior corresponding period.
Read in the 10-Q
During the first half of calendar year 2027 we expect to receive approximately $980.0 million (as of the date of the announcement), of cash proceeds related to the sale of our Fermacell business, subject to customary adjustments for net debt and working capital as of closing. Management expects these proceeds to further enhance the Company's liquidity position and expects to apply approximately $600.0 million of the proceeds toward debt repayment, with the remainder available for general corporate purposes, including share repurchases and working capital needs.
Read in the 10-Q
Market risk
In August 2026, we entered into foreign currency forward contracts to hedge our exposure to fluctuations in exchange rates associated with the anticipated Euro-denominated proceeds from the sale of our Fermacell business. The forward contracts are intended to reduce the variability in the U.S. dollar value of those proceeds resulting from fluctuations in the Euro-to-U.S. dollar exchange rate.
Read in the 10-Q
Share sales and buybacks
On August 20, 2026, our Board of Directors approved and authorized a new share repurchase program for an aggregate amount up to $250 million through August 20, 2027. Under the repurchase program, the Company may purchase its shares from time to time through open-market purchases, accelerated share repurchases or other methods as determined by the Company, subject to market conditions and other relevant conditions. For the three months ended September 30, 2026, no repurchases were made under this program, and $250 million remained available for repurchase as of September 30, 2026.
Read in the 10-Q
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Nov 5, 2026 against Item 1A of the 10-K filed May 19, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted).
Text on the page, not a score; each links to the filing at sec.gov.
What the 10-Q itself says about its risk factors:There have been no material changes to the risk factors previously disclosed in Part I, Item 1A, of our Annual Report on Form 10-K for the fiscal year ended March 31, 2026.
Read in the 10-Q
1 paragraph in the 10-Q's Item 1A, and none of them adds, rewords or quietly edits a paragraph of the 10-K's.
Sources
Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.
Also
10-K change: what was reworded or cut, section by section.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/JHX/export.csv") into a cell.